CADTH Canadian Drug Expert Committee recommendation: Dolutegravir/Rilpivirine (Juluca -- ViiV healthcare) indication : the treatment of human immunodeficiency virus (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL)
The CADTH Canadian Drug Expert Committee (CDEC) recommends that dolutegravir/rilpivirine (DTG/RPV) be reimbursed as a complete regimen to replace the current antiretroviral (cARV) regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically stabl...
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2018, June 2018
|
Edition: | Version 1.0. (Final) |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that dolutegravir/rilpivirine (DTG/RPV) be reimbursed as a complete regimen to replace the current antiretroviral (cARV) regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically stable and suppressed (i.e., fewer than 50 copies per mL of HIV-1 ribonucleic acid [RNA]), if the following criterion and condition are met: Under the care of a practitioner experienced in the care of patients with HIV; A reduced price |
---|---|
Physical Description: | 1 PDF file (6 pages) |